树懒
Lv5
1530 积分
2022-02-28 加入
-
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial
2个月前
已完结
-
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial
2个月前
已完结
-
Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives
2个月前
已完结
-
戈舍瑞林治疗子宫内膜异位症的临床效果研究
2个月前
已完结
-
Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial
2个月前
已完结
-
BRCA-CRisk: A Contralateral Breast Cancer Risk Prediction Model forBRCACarriers
2个月前
已完结
-
仿制药一致性评价与全面质量管理一体化的解析
2个月前
已完结
-
谈原研药与仿制药的不同
2个月前
已完结
-
专家深度访谈:与仿制药相比,原研药的优势有哪些?——以阿卡波糖为例
2个月前
已完结
-
治疗转移性乳腺癌新药——甲磺酸阿贝西尼(abemaciclib mesylate)
2个月前
已完结